USP15 is significantly down-regulated in CML, and its inhibition decreases de-ubiquitination of caspase-6 and promotes the degradation of caspase-6, which attenuates CML cell apoptosis and contributes to imatinib resistance [41]. This evidence concerns the gene CASP6 and chronic myelogenous leukemia, BCR-ABL1 positive.